DENVER– Palantir Technologies Inc. (Palantir, NYSE: PLTR) a leading builder of operating systems across the U.S. Government, announced it had been selected by the Centers for Disease Control and Prevention (CDC) to expand its role as a trusted technology partner in the federal COVID-19 response by supporting key distribution and supply-chain efforts.
The Department of Health and Human Services selected Palantir in mid-2020 to power Tiberius, the platform originally configured to support vaccine distribution. Building on its successful implementation of Tiberius, the government will be able to leverage its existing technology investment in Palantir’s modular and flexible software platform to support additional workflows such as distribution of life-saving therapeutics.
This contract was awarded to Palantir by the CDC for $5.3 million for the duration of six months. Palantir’s software empowers organizations to effectively integrate their data, decisions, and operations. It is designed to scale with increasing complexity, making it particularly suited to bring data-driven solutions to some of the world’s most difficult problems, including management of COVID-19 vaccines, pediatric vaccines, therapeutics, and more.
“A successful federal response to COVID requires real time situational awareness to manage rapidly changing epidemiology,” said Dr. Bill Kassler, Palantir’s chief medical officer – USG. “Palantir’s technology provides public health officials, from the federal to the local levels, with the tools they need to make informed, up-to-date decisions about sending medications and other resources where they are needed most.”
“We are honored to support the CDC’s efforts in the fight against the COVID-19 pandemic and build upon our work at other U.S. government agencies,” said Akash Jain, president of Palantir USG. “Helping the government solve the most pressing public policy challenges, whether they be in defense, intelligence, or in today’s case, public health, is core to our company’s mission. We are humbled to continue to earn the trust of the CDC for this critical work.”
